BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17942608)

  • 1. Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach.
    Li W; Guentzel MN; Seshu J; Zhong G; Murthy AK; Arulanandam BP
    Clin Vaccine Immunol; 2007 Dec; 14(12):1537-44. PubMed ID: 17942608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.
    Murthy AK; Chambers JP; Meier PA; Zhong G; Arulanandam BP
    Infect Immun; 2007 Feb; 75(2):666-76. PubMed ID: 17118987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice.
    Li W; Gudipaty P; Li C; Henderson KK; Ramsey KH; Murthy AK
    Immunol Cell Biol; 2019 Jan; 97(1):85-91. PubMed ID: 30051926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis.
    Tifrea DF; Ralli-Jain P; Pal S; de la Maza LM
    Infect Immun; 2013 May; 81(5):1741-50. PubMed ID: 23478318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.
    Li W; Murthy AK; Guentzel MN; Chambers JP; Forsthuber TG; Seshu J; Zhong G; Arulanandam BP
    Infect Immun; 2010 Sep; 78(9):3942-9. PubMed ID: 20605976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection.
    Li W; Murthy AK; Guentzel MN; Seshu J; Forsthuber TG; Zhong G; Arulanandam BP
    J Immunol; 2008 Mar; 180(5):3375-82. PubMed ID: 18292563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encapsulation of Recombinant MOMP in Extended-Releasing PLGA 85:15 Nanoparticles Confer Protective Immunity Against a
    Sahu R; Dixit S; Verma R; Duncan SA; Smith L; Giambartolomei GH; Singh SR; Dennis VA
    Front Immunol; 2021; 12():660932. PubMed ID: 33936096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A limited role for antibody in protective immunity induced by rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge.
    Murthy AK; Chaganty BK; Li W; Guentzel MN; Chambers JP; Seshu J; Zhong G; Arulanandam BP
    FEMS Immunol Med Microbiol; 2009 Mar; 55(2):271-9. PubMed ID: 19281569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
    Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
    Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal vaccination with Chlamydia pneumoniae induces cross-species immunity against genital Chlamydia muridarum challenge in mice.
    Manam S; Chaganty BK; Evani SJ; Zafiratos MT; Ramasubramanian AK; Arulanandam BP; Murthy AK
    PLoS One; 2013; 8(5):e64917. PubMed ID: 23741420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.
    Chaganty BK; Murthy AK; Evani SJ; Li W; Guentzel MN; Chambers JP; Zhong G; Arulanandam BP
    Vaccine; 2010 Mar; 28(11):2323-9. PubMed ID: 20056182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele.
    Murthy AK; Cong Y; Murphey C; Guentzel MN; Forsthuber TG; Zhong G; Arulanandam BP
    Infect Immun; 2006 Dec; 74(12):6722-9. PubMed ID: 17015458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge.
    Pal S; Tifrea DF; Follmann F; Andersen P; de la Maza LM
    Vaccine; 2017 Mar; 35(13):1705-1711. PubMed ID: 28238632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge.
    Pal S; Favaroni A; Tifrea DF; Hanisch PT; Luczak SET; Hegemann JH; de la Maza LM
    Vaccine; 2017 May; 35(19):2543-2549. PubMed ID: 28385608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection.
    Cong Y; Jupelli M; Guentzel MN; Zhong G; Murthy AK; Arulanandam BP
    Vaccine; 2007 May; 25(19):3773-80. PubMed ID: 17349723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge.
    Murthy AK; Li W; Guentzel MN; Zhong G; Arulanandam BP
    Vaccine; 2011 Mar; 29(14):2519-22. PubMed ID: 21300093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.
    Li W; Murthy AK; Lanka GK; Chetty SL; Yu JJ; Chambers JP; Zhong G; Forsthuber TG; Guentzel MN; Arulanandam BP
    Vaccine; 2013 Nov; 31(48):5722-8. PubMed ID: 24096029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with the polymorphic membrane protein A reduces Chlamydia muridarum induced genital tract pathology.
    Müller T; Becker E; Stallmann S; Waldhuber A; Römmler-Dreher F; Albrecht S; Mohr F; Hegemann JH; Miethke T
    Vaccine; 2017 May; 35(21):2801-2810. PubMed ID: 28413133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge.
    Pal S; Tatarenkova OV; de la Maza LM
    Immunology; 2015 Nov; 146(3):432-43. PubMed ID: 26423798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The duration of Chlamydia muridarum genital tract infection and associated chronic pathological changes are reduced in IL-17 knockout mice but protection is not increased further by immunization.
    Andrew DW; Cochrane M; Schripsema JH; Ramsey KH; Dando SJ; O'Meara CP; Timms P; Beagley KW
    PLoS One; 2013; 8(9):e76664. PubMed ID: 24073293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.